Our Culture

What you believe and what you value as an organization matters. Discover the DNA of our firm.

Our People

Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.

News & Events

Read about some of the latest events, partnerships, and business highlights from Sands Capital.

Careers

At Sands Capital, we strive to hire exceptional talent who will live our values and support our efforts to deliver on our mission.

From aquaculture to semiconductors, European firms are quietly becoming global leaders in innovation, sustainability, and value creation.

In this episode of What Matters Most, Sands Capital Portfolio Manager and Sr. Research Analyst Danielle Menichella discusses the business’ journey from Taser maker to artificial intelligence-powered software developer. 

Executive Managing Director and Senior Portfolio Manager Brian Christiansen discusses the importance of candor, collaboration, and entrepreneurialism in creating a culture that promotes long-term thinking.

FPT has harnessed education to drive Vietnam’s digital transformation and human-capital development.

Philosophy & Approach

Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.

Our latest annual report offers a comprehensive view of how we add value through active stewardship.

Public Equity

Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.

Venture and Growth Equity

Sands Capital invests in innovative businesses across all stages of the growth spectrum

Content category: Announcements

Stewardship is most effective when linked to a core investment philosophy. In our 2024 stewardship report, we illustrate our value driven, long-term oriented, and horizontally integrated approach.
Sands Capital led CompScience’s $27.6M funding round, paving the way for enhanced AI capabilities, an expanded global team, deeper insurer partnerships, and extended reach into new industries.
Sands Capital led Cytovale’s $100 million Series D funding round, enabling commercial and operational expansion of IntelliSep, a rapid diagnostic test cleared by the Federal Drug Administration (FDA), that is transforming sepsis care for hospital emergency departments and health systems nationwide.
This latest funding will help enable the company’s continued growth, enhanced processes, upgraded tooling, expanded infrastructure, and increased supply chain resiliency.
On a quarterly basis, Sands Capital publishes a detailed look at portfolio carbon metrics, business engagement activity and a recent case study, voting decisions, and a business impact profile.
Load More